ArticleBMC veterinary research2019
Suspected neurological toxicity after oral application of fluralaner (Bravecto®) in a Kooikerhondje dog.
Article in BMC veterinary research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- A systematic review of fluralaner as a treatment for ectoparasitic infections in mammalian species.PeerJ · 2025Pooled it
- Myoclonus as a neurologic manifestation of hypoglycemia in dogs.Journal of veterinary internal medicine · 2026Article
- Phenotypic characterization of presumptive propriospinal myoclonus in young dogs (2013-2025).Journal of veterinary internal medicine · 2026Article
- Residue depletion and withdrawal period determination of fluralaner in edible tissues and eggs following oral administration in laying Hens.Poultry science · 2026Article
- Cloning, structural and functional characterization of the ABCB1 transporter of the Eurasian bullfinch (Frontiers in veterinary science · 2026Article
- Comparative analysis of isoxazoline activity on human and canine GABA receptors expressed in Xenopus oocytes.Parasites & vectors · 2025Article
- Pharmacological studies and pharmacokinetic modelling to support the development of interventions targeting ecological reservoirs of Lyme disease.Scientific reports · 2024Article
- Fecal elimination of fluralaner in different carnivore species after oral administration.Frontiers in veterinary science · 2024Article
- Article
- Pharmacokinetic and pharmacodynamic considerations for treating sarcoptic mange with cross-relevance to Australian wildlife.International journal for parasitology. Drugs and drug resistance · 2023Review
- The P450 genes of the cat flea,Current research in insect science · 2022Article
- Survey of canine use and safety of isoxazoline parasiticides.Veterinary medicine and science · 2020Article
- Afoxolaner as a Treatment for a NovelFrontiers in veterinary science · 2020Article
- Optimising systemic insecticide use to improve malaria control.BMJ global health · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough the new isoxazoline drug fluralaner (Bravecto®) is generally well tolerated in dogs, adverse drug reactions involving neurological dysfunction occurred in individual dogs. However, most of these cases are documented inadequately and none of them is reported and discussed in the literature. As isoxazoline drugs target neuronal chloride channels with a clear preference for invertebrates, they are considered to have a good safety profile. However, pharmacodynamic effects in the nervous system of vertebrates cannot be ruled out completely. CASE PRESENTATION: A seven-month-old female Kooikerhondje dog was treated with Bravecto® at the recommended dose. About 24 h after administration, the dog exhibited signs of neurological toxicity, including generalized ataxia, myoclonic jerks, tremor of head and body, muscle twitching and oral dysphagia. All symptoms were transient and the dog fully recovered without any treatment after 10 h.
conclusionThis case report describes transient occurrence of neurological dysfunction after administration of Bravecto®. It may help to better classify adverse drug reactions after application of isoxazoline drugs and documents a good prognosis even after occurrence of severe neurological dysfunction in the present case.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.